And

are now a part of the new and improved

Advertisement

Topic: Psoriasis

News | March 21, 2019

Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasis

Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration agreement with Sanofi, triggering an...

Read More

News | April 24, 2019

FDA Approves AbbVie's Skyrizi for Psoriasis

Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical...

Read More

News | February 27, 2019

FDA Approves Janssen's Tremfya One-Press

The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson is...

Read More

News | March 2, 2019

Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Study

UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American...

Read More

Advertisement

The Latest in Psoriasis

Advertisement

View more